COFEPRIS promotes regulatory cooperation in the Americas

Home/Policies & Legislation | Posted 12/12/2023 post-comment0 Post your comment

During the 60th Executive Council of the Pan American Health Organization (PAHO) held in Washington, DC, USA, on 25–28 September 2023, Alejandro Svarch Pérez, Head of the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), on behalf of the Mexican government, emphasized the need to strengthen healthcare systems based on primary care.

Latin America 1638px

This event brought together Health Ministers and leaders from countries in the Americas with the aim of discussing strategies, decisions, and policies to strengthen healthcare personnel, prevent and control non-communicable diseases in children and young people, as well as improve mental health and suicide prevention following the COVID-19 pandemic, among other critical public health issues.

According to Svarch Pérez, ‘We agree on the utmost importance of strengthening healthcare systems based on primary care, following the spirit of Alma-Ata’.

The Alma-Ata Declaration on Primary Health Care emerged from the meeting held in 1978, where health was recognized as a human right, and the goal of achieving health for all by the year 2000 was established.

Svarch Pérez emphasized that intersectoral work guided by the sole objective of safeguarding the health of the Mexican population has allowed progress in necessary regulatory aspects. He also highlighted that, ‘It is imperative to strengthen the synergy among the regulatory authorities in the Americas. The Mexican Ministry of Health, through COFEPRIS, in close collaboration with sister countries such as Argentina, Brazil, Chile, Colombia, and Cuba, and with the support of the PAHO, is in the process of establishing the Regional School of Health Regulation to consolidate a space for academic teaching and exchange of experiences on regulatory sciences that will allow us to advance towards health sovereignty.’

In this context, the leader of COFEPRIS reaffirmed Mexico's faith in Jarbas Barbosa da Silva's leadership at the helm of the PAHO, with the aim of promoting collaboration between countries to enhance public health in the region.

It is worth noting that the development of biological and biotechnological products in Latin America is very diverse due to the specificities related to various factors such as cultural, economic, political, and regulatory factors. Therefore, each Latin American country has a unique market and regulatory landscape [1].

Related articles      
The effects of regulation on innovation in Mexican pharmaceutical industry

Regulatory landscape for biosimilars in Latin America

Collaboration between regulatory authorities for biosimilars

Regulatory issues related to quality of biosimilars

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Genfar: La nueva marca de genéricos de Eurofarma en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Genfar: La nueva marca de genéricos de Eurofarma en América Latina

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Regulation of the registration of biological drugs in Latin America[]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Dec 12]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Panama embraces international pharmacovigilance standards
Pharmacovigilance V13F21
Home/Policies & Legislation Posted 09/07/2024
FDA proposal to remove biosimilar interchangeability status in FY25
01 AA007239
Home/Policies & Legislation Posted 12/06/2024
MHRA unveils strategy for regulating AI technologies
23 AA011020
Home/Policies & Legislation Posted 22/05/2024
Regulatory Certainty Strategy for biosimilars launched in Mexico
Home/Policies & Legislation Posted 09/04/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010